Skip to main
GHRS

GHRS Stock Forecast & Price Target

GHRS Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GH Research PLC has experienced a notable increase of approximately 22% in stock value, driven by positive developments related to its primary product candidate, GH001, which has shown promising efficacy and safety profiles in the treatment of Treatment-Resistant Depression (TRD). The company is poised to commence a global Phase 3 program for GH001 after receiving FDA approval to lift its clinical hold, paving the way for significant market opportunities and projected peak sales of over $1.4 billion in TRD alone. Additionally, positive endorsements regarding psychedelics from health officials, along with anticipated higher pricing for GH001 in line with competitors, bolster the company's outlook and support further growth potential.

Bears say

GH Research PLC faces significant headwinds that negatively impact its stock outlook, primarily due to potential delays in advancing its clinical trials and obtaining regulatory approvals for its mebufotenin therapies. The company may encounter challenges related to safety signals, adoption rates in a competitive market, and issues related to the efficacy of its product candidates as they progress through larger, longer trials. Additionally, as a clinical-stage biopharmaceutical company without current revenues, GH Research is vulnerable to risks associated with financing ongoing research and commercialization efforts, further complicating its path to market success.

GHRS has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GH Research PLC (GHRS) Forecast

Analysts have given GHRS a Strong Buy based on their latest research and market trends.

According to 7 analysts, GHRS has a Strong Buy consensus rating as of Mar 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GH Research PLC (GHRS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.